Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a condition that raises an understandable and common question: can gynaecomastia go away without treatment? The answer depends largely on the underlying cause and how long the condition has been present. Pubertal gynaecomastia often resolves naturally within months, whilst long-standing cases are far less likely to regress on their own. Understanding what drives the condition, when to seek medical advice, and what treatment options are available in the UK can help men and boys make informed decisions about their care.

Can Gynaecomastia Go Away on Its Own?

Pubertal gynaecomastia resolves spontaneously in 75–90% of adolescents within six months to two years, but cases persisting beyond 12–18 months are unlikely to regress naturally due to progressive fibrosis of glandular tissue.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a common condition that affects men and boys at various stages of life. One of the most frequently asked questions is whether it resolves without treatment, and the honest answer is: it depends on the underlying cause and the duration of the condition.

In many cases, particularly those arising during puberty, gynaecomastia does resolve spontaneously. Pubertal gynaecomastia typically appears between the ages of 10 and 14, and in the majority of adolescents it regresses naturally within six months to two years as hormone levels stabilise. Published estimates suggest that 75–90% of pubertal cases resolve without medical intervention (NHS; NICE CKS: Gynaecomastia).

However, when gynaecomastia persists beyond 12–18 months, spontaneous resolution becomes considerably less likely. Over time, the glandular tissue can undergo fibrosis — a process where soft, active breast tissue is gradually replaced by firmer, fibrous tissue — making natural regression increasingly unlikely. This is why early assessment matters: the sooner the cause is identified and addressed, the better the chances of resolution without surgical intervention.

It is important to note that prepubertal gynaecomastia (in boys before puberty begins) is uncommon and should be regarded as atypical. It warrants prompt referral for paediatric or paediatric endocrine assessment to exclude an underlying cause.

Finally, pseudogynaecomastia — the appearance of enlarged breasts due to excess fatty tissue rather than true glandular growth — may improve with weight loss and lifestyle changes, but this is a distinct condition from true gynaecomastia and should not be confused with it.

Common Causes and How They Affect Recovery

The prognosis for natural resolution depends on the cause; physiological cases carry the best outlook, whilst medication-induced gynaecomastia may improve after safely stopping the causative drug under medical supervision.

Understanding the cause of gynaecomastia is central to predicting whether it will resolve and how it should be managed. The condition arises from an imbalance between oestrogen and androgen activity in breast tissue, and this imbalance can stem from a wide range of sources.

Physiological causes — including neonatal, pubertal, and age-related gynaecomastia — are the most common and carry the best prognosis for natural resolution. In older men, declining testosterone levels alongside relatively stable oestrogen can tip the hormonal balance, though this form is less likely to resolve without treatment.

Medication-induced gynaecomastia is another significant cause. A range of commonly prescribed drugs are associated with the condition, including:

• Spironolactone (used for heart failure and hypertension)

• Cimetidine (the H2 receptor antagonist most clearly implicated; evidence for other H2 blockers is limited)

• Anabolic steroids and exogenous testosterone therapy

• Anti-androgens used in prostate cancer treatment (e.g., bicalutamide) and GnRH analogues (e.g., goserelin, leuprorelin)

• Finasteride and dutasteride (5-alpha reductase inhibitors used for benign prostatic hyperplasia and hair loss)

• Digoxin

• Ketoconazole (systemic use)

• Antiretrovirals, including some used in HIV treatment (e.g., efavirenz)

• Antipsychotics, particularly those that raise prolactin (e.g., risperidone, haloperidol)

• Antidepressants: the association is less well established and should be interpreted cautiously

When a causative medication is identified and safely discontinued — always under medical supervision — breast tissue changes may partially or fully regress, particularly if the drug has been taken for a relatively short period. Regression after stopping a causative drug can take several months and may be incomplete. Patients should never stop prescribed medication without first consulting their GP or specialist.

Underlying health conditions such as hypogonadism, hyperthyroidism, liver cirrhosis, and chronic kidney disease can also drive gynaecomastia. In these cases, effective management of the primary condition may lead to improvement, though complete resolution is not guaranteed.

Testicular tumours — including hCG-secreting germ cell tumours — are an important red-flag cause that must be excluded, particularly in younger men presenting with unilateral or rapidly progressive gynaecomastia. Clinical examination of the testes is an essential part of assessment, and testicular ultrasound should be arranged if any abnormality is found.

Opioid use (including prescribed and illicit opioids) can cause gynaecomastia via opioid-induced hypogonadism; cessation or dose reduction, where clinically appropriate, may support recovery. Cannabis has been reported as a possible contributing factor, though the evidence remains limited and debated. Cessation of illicit drug use may support recovery, but this should be discussed with a healthcare professional.

Addressing the root cause early remains the most effective strategy for improving outcomes.

Medical and Surgical Treatment Options Available in the UK

Tamoxifen (off-label, 10–20 mg daily) is the most used medical option in specialist settings, whilst subcutaneous mastectomy — alone or combined with liposuction — is the definitive surgical treatment; NHS funding is not routinely available.

When gynaecomastia does not resolve spontaneously and a reversible cause cannot be identified or corrected, medical or surgical treatment may be considered. In the UK, management is guided by clinical assessment, duration of symptoms, and the degree of psychological or physical impact on the patient.

Conservative measures should always be considered first. In pubertal cases, watchful waiting with reassurance is appropriate, as the majority resolve naturally. Analgesia (e.g., paracetamol or a short course of a non-steroidal anti-inflammatory drug) may help manage breast tenderness. Addressing causative factors — such as stopping an implicated medication, treating an underlying condition, or supporting weight management where pseudogynaecomastia is a component — should be prioritised.

Medical (pharmacological) treatment is generally most effective in the early stages, before significant fibrosis has occurred — ideally within 6–12 months of onset. Although no medications are specifically licensed by the MHRA for gynaecomastia, several are used off-label in specialist settings:

• Tamoxifen (a selective oestrogen receptor modulator, typically 10–20 mg daily in clinical studies) is the most commonly used agent and has demonstrated effectiveness in reducing breast tissue volume and tenderness. Known adverse effects include hot flushes, increased risk of venous thromboembolism (VTE), and, rarely, endometrial changes; it is contraindicated in certain circumstances and must be initiated and monitored by a specialist.

• Raloxifene is another option occasionally used in specialist endocrine or breast clinics, with a broadly similar adverse effect profile.

• Aromatase inhibitors such as anastrozole have been explored; evidence for their use remains more limited, and long-term use carries implications for bone health.

These medications are initiated and monitored by an endocrinologist or specialist, not in primary care, and are not routinely commissioned on the NHS for cosmetic indications. Patients taking any of these medicines should report suspected side effects to their prescriber and via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

NICE does not currently have a dedicated guideline for gynaecomastia management, but referral pathways exist through endocrinology and breast surgery services.

Surgical treatment is the most definitive option for established gynaecomastia, particularly where fibrosis is present or where the condition has persisted for more than 12–18 months. Surgical approaches include:

• Subcutaneous mastectomy — removal of glandular breast tissue

• Liposuction — used where fatty tissue is the predominant component

• A combination of both techniques in many cases

NICE has published Interventional Procedures Guidance on surgical treatment of gynaecomastia, which informs consent and governance for these procedures in the UK.

Surgery for gynaecomastia is generally considered a cosmetic procedure and NHS funding is not routinely available; however, eligibility criteria vary by local Integrated Care Board (ICB) policy, and exceptions may be made where there is significant psychological impact or a clear underlying medical cause. Patients should discuss referral options and local funding criteria with their GP. Those seeking surgical correction who do not meet NHS criteria will often need to access treatment through private providers.

When to See a GP About Breast Tissue Changes

See a GP promptly for any unilateral, hard, or rapidly growing breast lump, nipple discharge, or skin changes, as NICE NG12 allows urgent two-week wait referral to exclude male breast cancer.

Whilst gynaecomastia is most often benign, breast tissue changes in males should never be dismissed without proper evaluation. Knowing when to seek medical advice is an important aspect of patient safety.

You should contact your GP promptly if you notice:

• A lump or swelling beneath one or both nipples

• Breast tenderness or pain that is persistent or worsening

• Nipple discharge of any kind

• Skin changes over the breast, such as dimpling, puckering, or redness

• A rapidly growing or hard, irregular lump — which may warrant urgent assessment to exclude male breast cancer, a rare but real diagnosis

• Breast enlargement in a boy before puberty has begun, which requires prompt specialist assessment

Although male breast cancer accounts for less than 1% of all breast cancer cases in the UK, any unilateral (one-sided), hard, or irregular breast lump should be assessed without delay. Under NICE NG12 (Suspected Cancer: Recognition and Referral), GPs can refer men with suspicious breast findings via the two-week wait (2WW) pathway to a specialist breast clinic. Breast imaging — ultrasound and/or mammography — may be arranged as part of this pathway.

For less urgent presentations — such as bilateral, soft, and tender breast tissue in an adolescent or a man who has recently started a new medication — a routine GP appointment is appropriate. Your GP will take a full medical and medication history, examine the breast tissue and testes, and will typically arrange blood tests including:

• Liver function tests (LFTs), urea and electrolytes (U&Es), and thyroid function tests (TFTs)

• Morning serum testosterone, LH, FSH, and oestradiol

• Prolactin and beta-hCG

If testicular examination reveals any abnormality, a testicular ultrasound will usually be arranged to exclude a tumour.

Early assessment not only helps identify any serious underlying cause but also improves the likelihood of successful non-surgical management. If you are experiencing distress related to breast changes — whether physical discomfort or psychological impact on body image and confidence — do not hesitate to raise this with your GP, as referral to a specialist or appropriate support services can make a meaningful difference to quality of life.

Frequently Asked Questions